In an interesting observation, detectable tumour-specific CD8+ T cell responses were dominated by recognition of the p15E ERV antigen over two defined mutated neoantigens, with functional p15E-reactive clones composing up to ~20% of total CD8+ TILs in late-stage tumours. This evidence concerns the gene CD8A and neoplasm.